Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics, Inc. (ATOS)
:ATOS
ATOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.55 - $1.66
Previous CloseN/A
Volume314.80K
Average Volume (3M)1.65M
Market Cap
$101.76M
Enterprise Value$21.69M
Total Cash (Recent Filing)$65.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Aug 18, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding129,170,000
10 Day Avg. Volume2,070,263
30 Day Avg. Volume1,652,673
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.42K
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$5.63Price Target Upside631.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive topline data from the KARISMA-Endoxifen Phase 2 study demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density and was well tolerated.
FDA ApprovalPositive FDA feedback for Endoxifen provides a path to the IND for a registration enabling study in ER+/HER2- metastatic breast cancer.
Financial PerformanceAtossa remains well-capitalized with ~$65M in cash, providing sufficient runway well into 2027.
Bears Say
Development RisksWhile there are high risks due to the long development road and potential for clinical trial failures, the market potential of approximately a billion dollars presents high rewards for these risks.
Market CompetitionThe oral SERD space in second-line and beyond patients has become increasingly competitive, though to date, Phase 3 trials have only indicated a benefit in ESR1 mutant patients.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics, Inc.’s price range in the past 12 months?
Atossa Therapeutics, Inc. lowest stock price was $0.55 and its highest was $1.66 in the past 12 months.
What is Atossa Therapeutics, Inc.’s market cap?
Atossa Therapeutics, Inc.’s market cap is $101.76M.
When is Atossa Therapeutics, Inc.’s upcoming earnings report date?
Atossa Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2025 which is in 10 days.
How were Atossa Therapeutics, Inc.’s earnings last quarter?
Atossa Therapeutics, Inc. released its earnings results on May 13, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.057 by $0.007.
Is Atossa Therapeutics, Inc. overvalued?
According to Wall Street analysts Atossa Therapeutics, Inc.’s price is currently Undervalued.
Does Atossa Therapeutics, Inc. pay dividends?
Atossa Therapeutics, Inc. does not currently pay dividends.
What is Atossa Therapeutics, Inc.’s EPS estimate?
Atossa Therapeutics, Inc.’s EPS estimate is -0.06.
How many shares outstanding does Atossa Therapeutics, Inc. have?
Atossa Therapeutics, Inc. has 129,170,000 shares outstanding.
What happened to Atossa Therapeutics, Inc.’s price movement after its last earnings report?
Atossa Therapeutics, Inc. reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.057. Following the earnings report the stock price went up 5.952%.
Which hedge fund is a major shareholder of Atossa Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ATOS
Atossa Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.63 (631.17% Upside)
$5.63 (631.17% Upside)
Blogger Sentiment
Bullish
ATOS Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $9.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.44%
12-Months-Change
Fundamentals
Return on Equity
-34.87%
Trailing 12-Months
Asset Growth
-22.33%
Trailing 12-Months
Company Description
Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
ATOS Company Deck
ATOS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with notable reductions in operating costs and promising clinical advancements for (Z)-endoxifen, particularly in metastatic breast cancer. However, the financial impact of a write-off and decreased interest income offset some of these positives.View all ATOS earnings summariesATOS Stock 12 Month Forecast
Average Price Target
$5.63
▲(631.17% Upside)
Technical Analysis
Anixa Biosciences
―
Pliant Therapeutics
―
Senti Biosciences
―
Zura Bio
―
HilleVax, Inc
―
Ownership Overview
3.41% Insiders
7.85% Mutual Funds
0.04% Other Institutional Investors
83.79% Public Companies and
Individual Investors